Please use this identifier to cite or link to this item:
Title: Role of routine use of beta blockers after percutaneous coronary intervention for acute coronary syndrome.
Author: Peck, K.
Andrianopoulos, Nick
Parfrey, S.
Roberts, L.
Duffy, S.
Sebastian, M.
Clark, D.
Brennan, A.
Oqueli, Ernesto
Ajani, A.
Reid, C.
Freeman, M.
Teh, A.
Issue Date: 2018
Conference Name: 66th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 12th Annual Australia and New Zealand Endovascular Therapies Meeting.
Conference Date: August 2-5th
Conference Place: Brisbane, Queensland
Abstract: Background: Beta blockers are recommended for routine use after myocardial infarction. These recommendations are based on trials in the prepercutaneous coronary intervention (PCI) era. There is a paucity of evidence supporting the use of beta blockers (BB) in patients undergoing PCI who have preserved left ventricular (LV) function. Method: Using a large PCI registry, data from patients with acute coronary syndrome (ACS) between 1 January 2005 and 30 June 2017 who were alive at 30-day follow-up were analysed. The aims were to evaluate BB use after PCI and its effect on mortality, and to review the subgroup of patients with a left ventricular ejection fraction (LVEF) < 35%. Results: Data from 17,568 patients were analysed; 83.2% were on BB. Patients on BB were younger (63.2 vs 65.4 years, p = 0.001) and more likely to be male (76.9% vs 73.4%, p = 0.001). Those not taking BB were more likely to have chronic lung disease (19.5% vs 8.5%, p = 0.001) and have a slower resting heart rate (70 vs 74 bpm, p = 0.001). National Death Index-linked mortality was lower in the BB group (13.1% vs 19.5%, p = 0.001) with mean follow-up of 5.3 ± 3.5 years. A subgroup analysis of those with LVEF < 35% (n = 815) showed that BB use was associated with a lower mortality (25.7% vs 44.8%, p = 0.001) and had a greater benefit than the overall cohort. Conclusion: Beta blocker use following ACS managed with PCI remained high in the PCI era. Beta blocker use was associated with a mortality benefit, particularly in those with an EF < 35%.
Internal ID Number: 01245
Health Subject: BETA BLOCKERS
Type: Conference
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.